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Introduction
Brachial plexus peripheral nerve blockade by local anesthetic injection may be utilized for postoperative pain control or surgical anesthesia. Although perineural catheters produce prolonged analgesia for days into the postoperative period, single-injection nerve blocks may be favored in some practices as they can be performed rapidly while still offering pain control in the immediate postoperative period. In order to prolong postoperative regional analgesia in peripheral nerve blocks with longacting local anesthetics, perineural adjuncts have become a topic of interest.
Dexamethasone is a perineural adjunct described to prolong both sensory and motor block [1] [2] [3] [4] [5] [6] [7] . The majority of studies have examined high doses of perineural dexamethasone (4-10 mg), primarily focused on upper extremity peripheral nerve blocks [2] [3] [4] [5] [6] .
To further investigate dexamethasone's effect as a perineural additive, we conducted a retrospective evaluation of our regional anesthesia quality assurance database, used to follow patients who received a single injection peripheral nerve block. Our primary aim was to examine the effect of perineural dexamethasone on peripheral nerve block duration. Secondary aims included evaluation of block duration by location, effect of dexamethasone on rebound pain, and examination of factors impacting patient satisfaction.
Methods
Following institutional review board approval, data from 1,942 consecutive patients entered into our regional quality assurance database between January 31, 2014, and May 18, 2015, after peripheral nerve block placement were evaluated.
In our institution, all patients receiving peripheral nerve blocks are entered into a quality assurance database to evaluate block effectiveness (block duration, analgesia quality, and patient satisfaction), block resolution, block related complications, and analgesic transition to systemic medications. A member of the regional anesthesia pain service contacts patients by inpatient visit or outpatient phone call each day after surgery until the nerve block resolves. Block duration is defined as the time between block placement and the time the patient reports complete resolution of numbness in the blocked extremity. This method has been previously described by Rasmussen et al. [8] . Numeric pain scores were assessed daily until block resolution. Pain scores were collected preoperatively by asking, "What number level would you rate your pain today, if zero is no pain and ten is the worst pain you could ever imagine?" Postoperatively, pain scores were collected by asking, "What number level would you rate your pain when the block was completely gone, if zero is no pain and ten is the worst pain you could ever imagine?" Patient satisfaction was assessed at the time of block resolution as poor, fair, good, very good, and excellent. All perineural dexamethasone utilized was preservative free.
Exclusion criteria for analysis included patients receiving multiple peripheral nerve blocks, local anesthetics other than ropivacaine, use of other perineural additives, perineural catheter placement, block duration not recorded, and dexamethasone dose greater than 4 mg. Rebound pain was calculated as the last collected postoperative numeric rating scale pain score (collected after block resolution) minus the preoperative numeric rating scale pain score.
Statistical Analysis
Descriptive statistics were calculated for all patients' baseline characteristics and clinical information. For all analyses examining associations with perineural dexamethasone use, dexamethasone dose was considered in three categories: none (0 mg), very low dose (2 mg or less), or low dose (greater than 2 mg to 4 mg). Univariate associations between the perineural dexamethasone dose groups with continuous variables were examined using a general linear regression approach, and associations with categorical variables were examined using chi-square tests or Fisher's exact tests where appropriate. Univariate associations between block duration and each predictor of interest were examined using a series of general linear regression models. Additionally, a subgroup analysis of the impact of dexamethasone dose group on block duration within each block type was also conducted using a univariate linear regression approach.
A multiple linear regression model was developed to examine associations between procedural and patient variables with block duration. All independent variables with P < 0.2 in univariate models were considered in the multivariable model. All variables with a multivariable significance of P < 0.05 were retained in the final model. The main association of interest in univariate and multivariable models was the association between block duration and perineural dexamethasone dose group. Thus pair-wise comparisons of block duration between perineural dexamethasone dose groups were conducted for the univariate and multivariable models with the significance level adjusted for multiple comparisons based on the Tukey-Kramer approach. Model assumptions were checked graphically and were found to be met.
The association between patient satisfaction and procedural variables was also examined. Patient satisfaction was recorded in the database on a five-level ordinal scale: poor, fair, good, very good, and excellent. However, as very few patients answered "poor" or "fair," the patient satisfaction score was redefined into two categories: 1) poor, fair, or good vs 2) very good or excellent. All variables with univariate associations with patient satisfaction of P < 0.2 were considered in a multiple logistic regression model. All variables with a multivariable significance of P < 0.05 were retained in the final model. Model assumptions were checked graphically and were found to be met. The significance level for pair-wise comparisons of patient satisfaction between perineural dexamethasone dose groups was based on the Tukey-Kramer approach. All analyses were conducted in SAS v. 9.4.0 (SAS Institute, Cary, NC, USA).
Results
Patient inclusion is detailed in a CONSORT flow diagram ( Figure 1 ). Exclusion criteria resulted in the removal of 915 patients and inclusion of 1,027 patients.
Patient and peripheral nerve block characteristics separated by perineural dexamethasone use are presented in Table 1 . Almost all blocks (90.6%) included perineural dexamethasone: 537 patients received 2 mg or less (very low-dose group), 393 subjects received greater than 2 mg up to 4 mg (low-dose group), and 97 patients did not receive any dexamethasone. Specifically, in the very low-dose group, 524 patients received 2 mg and 13 patients had another dose (0.8, 1, 1.5, 1.6, and 1.8 mg). In the low-dose group, 373 patients received 4 mg and 20 patients received another dose (2.5, 2.8, and 3 mg). The median dose of perineural dexamethasone administered for all subjects was 2 mg. The use of any perineural dexamethasone increased mean block duration by 5.29 hours when all brachial plexus blocks were examined as a group (P < 0.001). Additionally, patients who received perineural dexamethasone were more likely to have a lower ASA Physical Status Classification (ASA status) (P ¼ 0.010).
Univariate and multivariable analyses for variables impacting block duration are presented in Table 2 . In the univariate models, patients who received perineural dexamethasone reported an increase in mean block duration with low-dose (20.2 hours) or very low-dose (19.2 hours) dexamethasone compared with ropivacaine alone (14.3 hours; P < 0.001 for both). Patients who received low-dose dexamethasone reported a mean block duration one hour longer relative to patients who received very low-dose dexamethasone (P ¼ 0.026). Increased local anesthetic dose (P ¼ 0.008), increased age (P ¼ 0.048), and female gender (P ¼ 0.024) were also associated with longer block durations in univariate models.
In the multivariable model for block duration (Table 2) , patients who received perineural dexamethasone continued to report an increase in mean block duration with low-dose (5.7 hours' increased duration) or very low-dose (5.1 hours' increased duration) dexamethasone compared with ropivacaine alone after controlling for other factors (P < 0.001 for both) ( Figure 2 ). However, block duration did not differ between patients receiving very low-dose or low-dose perineural dexamethasone (P ¼ 0.30). Increased local anesthetic dose (P ¼ 0.01), increased age (P ¼ 0.03), and female gender (P ¼ 0.03) continued to be associated with prolonged block duration in the multivariable model. The R 2 value for the multiple linear regression model was 0.09.
The impact of both very low-dose and low-dose perineural dexamethasone was also evaluated by block location (Figure 3 Data represent the mean change in block duration (hours) between groups or for a specific increase estimated from the regression models. CI ¼ confidence interval. *Global P values for any difference in block duration by perineural dexamethasone dose group. † P value adjusted for multiple comparisons based on Tukey-Kramer adjustment. § Rebound pain was calculated as the last collected postoperative numeric rating scale pain score (collected after block resolution) minus the preoperative numeric rating scale pain score. Patients were not specifically asked to define pain with movement vs rest. In addition to the above presented results, which treated perineural dexamethasone dose as a categorical variable, when perineural dexamethasone dose was evaluated as an ordinal variable, a linear trend was noted in which rebound pain decreased with an increased dose of perineural dexamethasone (P ¼ 0.034).
both). Block duration did not differ between very lowdose and low-dose perineural dexamethasone groups in either interscalene (P ¼ 0.051) or supraclavicular (P ¼ 0.956) block types. Given the small sample size in the infraclavicular and axillary block types, comparisons were not performed for these subcategories. 
Low-Dose Dexamethasone and Analgesic Duration
As patients with higher ASA status (III/IV) were less likely to receive perineural dexamethasone (Table 1) , a subgroup analysis for the univariate and multivariable models of block duration by dexamethasone dose was conducted, and data were subset by ASA status (I/II and III/IV). In the univariate models, low-dose and very low-dose perineural dexamethasone did not differ in the ASA III/IV patient subset. Otherwise, in both univariate and multivariable models, the results did not differ by ASA status and both low-dose and very low-dose dexamethasone prolonged reported block durations compared with no dexamethasone. In the multivariable analysis, regardless of ASA status, block duration did not differ for low-dose and very low-dose dexamethasone.
Mean rebound pain (6SD) across all blocks collected was 0.9 (63.5) and did not vary between groups (P ¼ 0.081). However, when perineural dexamethasone dose was evaluated as an ordinal variable, this revealed a linear trend in rebound pain with increasing dose of perineural dexamethasone (P ¼ 0.034). Specifically, higher dexamethasone doses were associated with decreased rebound pain compared with no perineural dexamethasone doses.
Most subjects reported satisfaction as "excellent" (63.6%) or "very good" (30.9%). For analysis, patient satisfaction was categorized as excellent or very good vs good, fair, or poor. In univariate logistic regression models, patient satisfaction was only associated with very low-dose perineural dexamethasone compared with not receiving perineural dexamethasone for both univariate and multivariable models (Table 3 ). In comparison with ropivacaine alone, utilization of very low-dose perineural dexamethasone was associated with a 2.7-fold increase in the odds of a patient reporting excellent or very good satisfaction. Increased age was also associated with increased satisfaction in the multivariable mode. All other variables examined did not impact patient satisfaction including low-dose dexamethasone and block duration.
Discussion
Perineural dexamethasone has been shown to be a promising additive for prolonging peripheral nerve block duration. Due to potential concerns for neurotoxicity with larger doses of perineural dexamethasone [9] , it may be beneficial to utilize very low dexamethasone doses (2 mg) if these blocks provide similar increases in block duration. This retrospective evaluation of a large quality assurance database sought to examine whether low doses (greater than 2 mg to 4 mg) and very low doses (2 mg or less) of perineural dexamethasone led to prolonged nerve block prolongation compared with ropivacaine alone in a cohort of more than 1,000 patients. Our findings confirm the utility of very low-and lowdose perineural dexamethasone to prolong interscalene and supraclavicular brachial plexus nerve block duration. Notably, while increased block duration was associated with low-dose dexamethasone compared with very low-dose dexamethasone in univariate analysis, block duration did not differ in the multivariable model.
Most publications examining and demonstrating prolonged block duration with perineural dexamethasone have utilized higher dexamethasone doses [1] [2] [3] [4] [5] [6] [7] [8] . Prior studies have reported median interscalene block durations of 22.2 hours and 22.4 hours when combining 30 mL of 0.5% ropivacaine with 8 mg and 10 mg of perineural dexamethasone, respectively [2, 3] . Both of these durations greatly exceeded the median durations of ropivacaine alone (11.8 hours and 12.6 hours, respectively). Similarly, Abdallah et al. [5] reported 25 hours for mean supraclavicular nerve block duration when combining 30 mL 0.5% bupivacaine with 8 mg of perineural dexamethasone compared with a 13.2-hour mean duration with bupivacaine alone. A large retrospective database analysis with a similar design to our study reported comparable results to these randomized clinical trials [8] . Evaluating more than 1,000 peripheral nerve blocks, investigators found a median block duration of 15 hours for ropivacaine alone compared with 22 hours when 4 or 8 mg of perineural dexamethasone was added [8] . Although these studies validate the utility of perineural dexamethasone, there have also been concerns regarding neurotoxicity when using these high doses [9] .
Williams et al. [9] investigated toxicity with perineural additives through in vitro studies examining isolated sensory neuron cell bodies, which are more vulnerable than distal axons to toxins and maximize the sensitivity of toxicity assays. Following exposure to ropivacaine, clonidine, buprenorphine, dexamethasone, and midazolam in various concentrations, combinations, and durations, cell death at 24 hours was greatest in the ropivacaine (0.25%) alone group. Neurotoxicity associated with ropivacaine combined with clonidine, buprenorphine, and dexamethasone was comparable with that of ropivacaine alone. Dexamethasone only exhibited neurotoxicity at a high concentration when combined with clonidine, buprenorphine, and ropivacaine. While some have referred to this work as an indicator for perineural dexamethasone toxicity, the authors have cited their clinical work using perineural adjuncts without complications and have been proponents of using very low doses of perineural dexamethasone rather than higher doses [10, 11] .
Few prior publications have reported peripheral nerve block duration with doses of dexamethasone of 4 mg or less. Our reported mean block durations for very low-dose and low-dose dexamethasone are slightly less than prior studies, although our ropivacaine alone mean block duration lies in the middle of reported ranges [1] [2] [3] [4] [5] [6] [7] [8] . As many previous reports utilized greater doses of perineural dexamethasone [2, 3, 5, 8] , this could explain our 19-to 20-hour duration compared with the more common 21-22 hours published with perineural dexamethasone. However, Liu et al. [12] examined low-dose perineural dexamethasone (1, 2, and 4 mg) combined with 30 mL of 0.25% bupivacaine in supraclavicular blocks and reported similar median analgesia duration in every group (22.3, 23.3 , and 21.2 hours, respectively). These durations were all greater than their median duration for bupivacaine alone (12.1 hours) and are comparable with the 21-to 22-hour durations reported by multiple studies evaluating higher perineural dexamethasone doses. Similar to Liu et al., our data indicate that very low-dose perineural dexamethasone effectively prolongs patient-reported analgesia with ropivacaine peripheral nerve blocks. This suggests that practices should transition away from high (8-10 mg) to very low perineural dexamethasone doses as prior reports have recommended [10] .
Rebound pain after nerve block resolution can create a negative postoperative experience. In a multivaraible analysis of patients undergoing anterior cruciate ligament surgery with continuous femoral nerve blocks infused with levobupivacaine or saline, they concluded that prolonging nerve block duration by 33 hours reduced rebound pain scores by one unit on the 0-10 numeric rating pain scale [13] . A large quality assurance study analyzing multiple perineural additives (dexamethasone, buprenorphine, and clonidine) that were added in varying doses to bupivacaine peripheral nerve blocks examined rebound pain [14] . Increased rebound pain was associated with higher preoperative pain score and increased dexamethasone dose (4 mg total vs 2 mg total; P < 0.001). The authors concluded that perineural dexamethasone doses "other than 2 mg total" may be associated with higher rebound pain.
Hyperalgesia following block resolution has also been explored in the rodent model. Following sciatic nerve blocks in rats with 0.5% ropivacaine, hyperalgesia to thermal stimulus was noted after nerve block resolution [15] . While a similar hyperalgesic response to thermal stimulation was noted in bupivacaine only sciatic nerve blocks in mice, this hyperalgesia was lost when perineural dexamethasone was administered with bupivacaine in low (0.14 mg/kg) and high (0.5 mg/kg) doses [16] .
In our study, rebound pain scores did not differ with perineural dexamethasone utilization when analyzed in three categorical groups (none, very low-dose, and low-dose dexamethasone). However, when perineural dexamethasone dose was evaluated as an ordinal variable, this revealed a linear trend in which rebound pain decreased with an increased dose of perineural dexamethasone (P ¼ 0.034). These data contrast with the previously mentioned findings of Williams et al. [14] , in which dexamethasone doses greater than 2 mg were associated with increased rebound pain. However, Williams et al. [14] specified "preop pain score with movement" and "postop pain score with movement," while our study did not identify pain with movement. Conversely, increased patient satisfaction was only associated with the use of very lowdose perineural dexamethasone in both univariate and multivariable models. The potential benefit of perineural additives on rebound pain and patient satisfaction should be further explored in a prospective clinical model.
Other factors associated with increased block duration in our data included increased local anesthetic dose, female gender, and increased age. Past studies have all examined the impact of these variables on block duration, with mixed results [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . It is also notable that our mean ropivacaine volume was 23.1 mL. This volume is lower than the majority of prior studies, which have commonly utilized 30 mL [2, 3, 5] .
It remains uncertain if the improved analgesia by perineural dexamethasone administration is due to a perineural vs a systemic effect; however, the vast majority of studies investigating this have examined high doses of dexamethasone (8-10 mg). While it is notable that some comparisons of perineural to systemic dexamethasone have reported comparable nerve block duration and analgesia [3, 5, 29] , the dexamethasone dose administered (8 mg) was likely much closer to the 0.1-mg/kg dexamethasone dose previously shown to provide systemic analgesia [30] . Conversely, 4 mg of perineural, but not intravenous, dexamethasone was shown to prolong analgesic duration of a single-injection interscalene block with 0.75% ropivicaine [4] . Similarly, a loss of Low-Dose Dexamethasone and Analgesic Duration rebound hyperalgesia mediated by heat fibers was noted with perineural but not systemic dexamethasone in an animal model [16] .
Our data found block duration to be prolonged when all brachial plexus blocks were examined as a group. When blocks were examined separately, increased duration was noted in both interscalene and supraclavicular approaches; however, we had an inadequate number of patients to further examine infraclavicular and axillary blocks. As most prior studies have examined the interscalene and supraclavicular techniques, more research may be needed to determine if nerve block prolongation by dexamethasone is specific to nerve block location.
Although these data were collected prospectively for quality assurance monitoring, this is a retrospective study and has associated limitations. First, peripheral nerve blocks were placed by numerous providers with variable skill, although an attending physician on the regional anesthesia team was always involved with block placement. Additionally, measurement of block duration may be biased as it was based on the patient's perception of block resolution. However, the authors feel this may be mitigated as what a patient perceives may be as valuable as other methods of determining block length (i.e., external examiner). This method of determining block duration when analyzing large populations has also been previously published [8, 14] . Our data are further limited by the small number of patients who did not receive dexamethasone. Next, the patient's postoperative analgesic medications and frequency were determined by surgeon preference. This was likely variable and could have influenced the patient's pain scores at time of block resolution and our calculated rebound pain scores. Additionally, numerous factors affect postoperative pain scores (e.g., postoperative analgesic regimen, surgical procedure) that cannot be accounted for in a retrospective evaluation and undoubtedly affect our evaluation of rebound pain. Further, we are not able to extrapolate why patients did or did not receive perineural dexamethasone as this is difficult to capture in a quality assurance database. Last, we did not control for dexamethasone being given intravenously for postoperative nausea and vomiting (PONV) prophylaxis. It is unknown if a patient's nerve block duration could have been affected if they had received intravenous dexamethasone for PONV prophylaxis.
In conclusion, the results of this retrospective database analysis demonstrate that very low and low doses of perineural dexamethasone are associated with prolonged interscalene and supraclavicular brachial plexus block duration compared with ropivacaine alone. However, reported block durations were not greater with low-dose compared with very low-dose perineural dexamethasone in a multivariable model and indicate that very low doses may be considered if dexamethasone is utilized as a perineural adjunct.
